# psoriasis - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 15915
- Completion tokens: 5432
- Reasoning tokens: 0
- Total tokens: 21347
- API requests reported: 1
- Elapsed seconds: 152.282
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## 1. Overall biological interpretation

The 100-gene signature is highly asymmetric: **90 genes are upregulated and 10 are downregulated**, and all 100 have **FDR ≤ 0.01**. The dominant pattern is a coordinated psoriatic-lesion program involving:

- strong activation of **IL-36/IL-20-family inflammatory signaling**;
- marked induction of **epidermal antimicrobial peptides**;
- abnormal **keratinocyte differentiation, cornified-envelope formation, and barrier remodeling**;
- evidence of **myeloid/neutrophil-associated inflammation and chemotactic recruitment**;
- increased **epidermal stress/proliferation and tissue-remodeling signals**.

The strongest effects include **IL36A** (log2FC 11.373575, FDR 1.6547603e-98), **DEFB4A** (11.182922, FDR 2.1809413e-69), **DEFB4B** (11.030811, FDR 3.6960582e-71), **S100A7A** (9.8326673, FDR 9.2520185e-63), **PI3** (9.2403801, FDR 1.5318976e-69), and **SERPINB4** (9.1181363, FDR 6.6807271e-66). This is biologically consistent with inflamed, hyperplastic, antimicrobial-active psoriatic epidermis.

However, **external statistical validation was not performed**: no independent-cohort effect sizes, P values, or FDR values were supplied. The pathway, tissue, network, and literature records therefore support biological plausibility but do not constitute replication or proof of causality.

## 2. Core biological programs

### Program 1: IL-36/IL-20-family inflammatory epithelial signaling

- **Direction:** Strongly upregulated inflammatory program.
- **Supporting genes:** `IL36A`, `IL36G`, `IL36RN`, `IL19`, `IL20`, `IL26`, `IRAK2`, `ZC3H12A`, `CD274`.
- **Relevant pathways:**  
  - Reactome: **Interleukin-36 pathway** and **Interleukin-20 family signaling**  
  - KEGG: **IL-17 signaling pathway** and **cytokine-cytokine receptor interaction**
- **Interpretation:** The simultaneous induction of IL-36 agonists (`IL36A`, `IL36G`), the antagonist `IL36RN`, and related epithelial cytokines (`IL19`, `IL20`, `IL26`) indicates an activated cytokine circuit rather than an isolated cytokine abnormality. `IL36RN` may represent a compensatory feedback response to increased IL-36 activity. `IRAK2` and `ZC3H12A` are compatible with altered inflammatory signal processing, although the expression data do not establish their functional direction.
- **Evidence strength:** **Strong supported hypothesis.** Direct transcriptomic evidence is exceptionally strong and coherent across several cytokine genes. Reactome, QuickGO, and UniProt annotations support pathway membership and the antagonist role of IL36RN; UniProt records that IL36RN inhibits IL36A/IL36G signaling through IL1RL2 and IL1RAP. STRING reports an interaction network involving IL36RN, IL36G, IL1RL2, and IL1RAP.
- **Limitations:** The supplied results do not show pathway activity, protein abundance, receptor activation, or causal direction. The provided KEGG/Reactome labels are annotation results, not a newly computed enrichment P value. IL-17 pathway involvement is plausible but no IL17A or IL17F measurement is present in this 100-gene subset.

### Program 2: Antimicrobial and innate epithelial defense

- **Direction:** Strongly upregulated.
- **Supporting genes:** `DEFB4A`, `DEFB4B`, `DEFB103A`, `DEFB103B`, `PI3`, `S100A7`, `S100A7A`, `S100A8`, `S100A12`, `TCN1`, `SERPINB3`, `SERPINB4`.
- **Relevant pathways/terms:**  
  - GO: **Antimicrobial humoral response**  
  - GO: **Response to lipopolysaccharide**  
  - KEGG: **Staphylococcus aureus infection** and **IL-17 signaling pathway**
- **Interpretation:** The coordinated induction of multiple β-defensins, protease inhibitors, and S100-family proteins indicates a broad antimicrobial and danger-response state in lesional skin. The magnitude is particularly notable for `DEFB4A` and `DEFB4B`, each approximately 11 log2-fold higher than control in the supplied results.
- **Evidence strength:** **Strong supported hypothesis.** This program is supported directly by many independent genes with concordant direction and by GO/KEGG annotations. The S100A7 network record connects `S100A7` with `FABP5`, `S100A12`, `S100A7A`, `SERPINB3`, and `SERPINB4`, but these relationships should be regarded as database-supported associations unless a specific physical interaction is documented.
- **Limitations:** Antimicrobial-gene expression can reflect both keratinocyte activation and increased inflammatory-cell abundance. It does not demonstrate altered antimicrobial function, microbial overgrowth, or a specific pathogen in the lesions. The “Staphylococcus aureus infection” KEGG label is a shared host-response annotation, not evidence that S. aureus caused the observed disease state.

### Program 3: Epidermal differentiation, cornified envelope, and barrier remodeling

- **Direction:** Strongly upregulated, with additional evidence of altered epithelial homeostasis.
- **Supporting genes:** `SPRR2A`, `SPRR2B`, `SPRR2D`, `SPRR2E`, `SPRR2F`, `SPRR2G`, `SPRR3`, `LCE3A`, `LCE3D`, `KRT6A`, `GJB2`, `GJB6`, `TMPRSS11D`, `KLK13`, `SERPINB3`, `SERPINB4`.
- **Relevant pathway:** Reactome **Formation of the cornified envelope (R-HSA-6809371)**; GO **epidermis development**.
- **Interpretation:** The coordinated increase in small proline-rich proteins, late cornified envelope genes, keratin 6A, connexins, kallikrein/protease-associated genes, and serpin genes supports abnormal epidermal maturation and barrier restructuring. This is a program-level signal because many genes from related structural and protease-regulatory families move together.
- **Evidence strength:** **Strong supported hypothesis.** Direct gene-level evidence is broad, and the supplied Reactome annotation includes 12 genes from this signature. STRING records also show associations among SPRR2-family genes and between SPRR proteins and KRT6A.
- **Limitations:** The signature cannot distinguish adaptive barrier reinforcement from disordered differentiation. Bulk lesional skin may contain more keratinocytes or a different epidermis-to-dermis ratio than normal skin. Protein localization and barrier function were not measured.

### Program 4: Myeloid/neutrophil-associated inflammation and immune-cell recruitment

- **Direction:** Upregulated.
- **Supporting genes:** `S100A8`, `S100A12`, `CXCR2`, `TCN1`, `PLBD1`, `GPR15LG`, `CXCL13`, `ADAP2`, `TRIM15`.
- **Relevant terms/pathways:** GO **response to lipopolysaccharide**, cytokine/chemokine signaling, and the supplied KEGG inflammatory pathways.
- **Interpretation:** `S100A8` and `S100A12`, together with `TCN1`, `PLBD1`, and `CXCR2`, are compatible with increased myeloid and neutrophil-associated activity. `CXCL13` suggests altered leukocyte recruitment or lymphoid organization, but its cellular source is not resolvable from bulk expression.
- **Evidence strength:** **Moderate supported hypothesis.** The genes are directionally concordant and biologically related, and tissue-expression/network annotations support immune relevance.
- **Limitations:** This may primarily reflect **cellular composition**, not transcriptional reprogramming within resident keratinocytes. No leukocyte deconvolution, single-cell data, histology, or cell-type-specific expression was supplied. Direct regulatory links among these genes are not established by the dataset.

### Program 5: Epidermal stress, proliferation, and tissue remodeling

- **Direction:** Upregulated, with selected downregulated genes suggesting altered tissue homeostasis.
- **Supporting genes:** `KRT6A`, `RRM2`, `CCNE1`, `WNT5A`, `HPSE`, `PLA2G4D`, `PLA2G4E`, `FABP5`, `KYNU`; downregulated examples include `BTC` (log2FC -4.2989343) and `WAKMAR1` (log2FC -5.6275936).
- **Relevant pathways:** No single standardized pathway is sufficiently specific from the supplied annotations; relevant concepts include epithelial proliferation, lipid mediator metabolism, and extracellular-matrix/tissue remodeling.
- **Interpretation:** `RRM2` and `CCNE1` support increased cell-cycle activity, while `KRT6A`, `WNT5A`, `HPSE`, and phospholipase-related genes suggest epithelial stress and remodeling. The downregulated genes may represent loss of normal homeostatic or differentiation-associated signals, but their functions cannot be confidently integrated without additional annotation.
- **Evidence strength:** **Moderate for an exploratory program.** The direct expression pattern is coherent for epithelial activation, but this interpretation is less specific than the cytokine, antimicrobial, and cornified-envelope programs.
- **Limitations:** Proliferation cannot be inferred solely from two cell-cycle genes, and remodeling genes may be secondary consequences of inflammation. Formal gene-set enrichment statistics for this specific program were not supplied.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological interpretability, not because external database record counts establish higher statistical importance.

1. **IL36A–IL36G–IL36RN inflammatory module**  
   - `IL36A`: log2FC **11.373575**, FDR **1.6547601e-98**.  
   - `IL36G`: log2FC **5.6840917**, FDR **1.4283826e-90**.  
   - `IL36RN`: log2FC **3.0051655**, FDR **3.8506931e-62**.  
   - Role: central inflammatory epithelial signaling with apparent antagonist feedback.  
   - Relationship type: pathway co-membership and regulatory antagonism; STRING additionally reports IL36RN–IL1RL2 and IL36RN–IL36G associations. These are not equivalent to demonstrating a direct physical interaction in the present tissue.

2. **DEFB4A–DEFB4B–DEFB103A/B antimicrobial module**  
   - All are strongly upregulated; `DEFB4A` log2FC **11.182922** and `DEFB4B` log2FC **11.030811**.  
   - Role: epithelial antimicrobial defense.  
   - Relationship type: shared pathway/program and likely co-expression; the dataset does not establish direct protein-protein interaction.

3. **S100A7/S100A7A–S100A8/S100A12 inflammatory module**  
   - `S100A7`: log2FC **7.0947825**; `S100A7A`: **9.8326673**; `S100A8`: **7.7293672**; `S100A12`: **8.3288322**.  
   - Role: epithelial danger signaling plus myeloid-associated inflammation.  
   - Relationship type: co-expression and inflammatory-network association. STRING reports network links involving S100A7, but the supplied data do not show direct physical interaction among all four proteins.

4. **SPRR/LCE/KRT6A cornified-envelope module**  
   - Representative genes: `SPRR2A` log2FC **7.31208**, `SPRR3` **7.1797512**, `LCE3A` **8.2975962**, `LCE3D` **5.314054**, and `KRT6A` **4.3025579**.  
   - Role: abnormal keratinocyte differentiation and barrier remodeling.  
   - Relationship type: pathway co-membership and likely co-expression; STRING records associations among SPRR-family genes and KRT6A, but these should not automatically be called direct binding interactions.

5. **IL19–IL20–IL26 epithelial cytokine module**  
   - `IL19`: log2FC **7.5795008**; `IL20`: **5.6674194**; `IL26`: **4.3612172**.  
   - Role: cytokine-mediated communication between inflamed epidermis and immune/stromal compartments.  
   - Relationship type: cytokine-family/pathway co-membership and indirect signaling relationship, not direct interaction.

6. **CXCL13/CXCR2 immune-recruitment signals**  
   - `CXCL13`: log2FC **5.8933907**; `CXCR2`: **2.7005582**.  
   - Role: candidate recruitment or organization of inflammatory cells.  
   - Relationship type: indirect or putative chemotactic relationship; CXCL13 is not established here as a ligand for CXCR2, so these two genes should not be presented as a receptor-ligand pair.

7. **RRM2–CCNE1 proliferative module**  
   - `RRM2`: log2FC **2.7179913**, FDR **7.1178258e-62**; `CCNE1`: log2FC **2.5573733**, FDR **4.4959113e-61**.  
   - Role: compatible with increased cell-cycle activity in lesional epidermis.  
   - Relationship type: cell-cycle pathway co-membership; causality is not established.

8. **WNT5A–HPSE–PLA2G4D/E remodeling module**  
   - `WNT5A`: log2FC **2.5264849**; `HPSE`: **2.9241399**; `PLA2G4D`: **4.614801**; `PLA2G4E`: **2.4698712**.  
   - Role: putative noncanonical signaling, extracellular remodeling, and lipid-inflammatory mediator production.  
   - Relationship type: indirect pathway convergence; no direct interaction is demonstrated.

## 4. Validation priorities

### 1. Cell-composition and spatial validation  
**Classification:** Confounding or composition check

- **Why prioritize:** The S100A8/S100A12/TCN1/PLBD1/CXCR2 signal may reflect increased neutrophil or myeloid content, while the SPRR/LCE/KRT6A signal may reflect altered epidermal abundance.
- **Current evidence:** Strong differential expression, including `S100A8` log2FC **7.7293672** and `S100A12` **8.3288322**, plus coordinated epithelial structural changes.
- **External evidence:** Tissue-expression, HPA, GTEx, and network annotations support cell-type and tissue relevance, but they do not resolve composition in this cohort.
- **Next step:** Single-cell or spatial transcriptomics, immunohistochemistry for keratinocytes, neutrophils, macrophages, and T cells, and bulk RNA deconvolution using validated reference profiles.
- **Status:** **Established evidence** that the bulk signature differs between lesional and control skin; **supported hypothesis** for the specific cellular sources.

### 2. Functional testing of the IL-36 inflammatory circuit  
**Classification:** Mechanistic hypothesis

- **Why prioritize:** `IL36A`, `IL36G`, and the antagonist `IL36RN` form the most coherent cytokine module.
- **Current evidence:** `IL36A` is one of the largest effects in the dataset, and all three genes are significantly upregulated.
- **External evidence:** Reactome, UniProt, QuickGO, and STRING support IL-36 pathway membership and IL36RN antagonism through IL1RL2/IL1RAP. These sources are partly overlapping annotation/database evidence rather than independent cohort replication.
- **Next step:** Stimulate primary human keratinocytes or lesional organoids with IL-36 agonists; measure NF-κB/related signaling, defensin and IL-20-family induction, and test IL36RN or receptor blockade with rescue experiments.
- **Status:** **Supported hypothesis**, not demonstrated causality.

### 3. Lesional biomarker panel based on antimicrobial and barrier genes  
**Classification:** Biomarker

- **Why prioritize:** The combination of `DEFB4A/B`, `S100A7/A7A`, `PI3`, `SPRR` genes, and `LCE3A/D` captures both inflammation and epidermal remodeling.
- **Current evidence:** Large, concordant effects—for example, `DEFB4A` log2FC **11.182922**, `PI3` **9.2403801**, and `S100A7A` **9.8326673**.
- **External evidence:** GO, Reactome, and the supplied psoriasis literature record [PMID: **40560938**] provide contextual support for psoriasis-related biomarker investigation, but that record is not an independent statistical validation of this signature.
- **Next step:** Test the panel in an independent psoriasis cohort, including nonlesional skin and inflammatory dermatosis controls; assess RNA and protein levels and correlation with clinical severity or treatment response.
- **Status:** **Supported hypothesis**; not yet clinically validated.

### 4. IL-36 receptor-network and downstream-response validation  
**Classification:** Interaction / network hypothesis

- **Why prioritize:** The dataset suggests coordinated signaling among IL36A/G, IL36RN, IL1RL2, IL1RAP, and downstream epithelial-response genes.
- **Current evidence:** Upregulation of IL36A, IL36G, IL36RN, IRAK2, antimicrobial peptides, and IL-20-family cytokines.
- **External evidence:** STRING reports IL36RN interactions with IL1RL2, IL1RAP, IL36G, and related receptors; UniProt and Reactome support the receptor mechanism. This is external molecular-network evidence, not an interaction measurement in the samples.
- **Next step:** Use receptor-blocking antibodies or genetic perturbation, reporter assays, phosphoproteomics, and co-immunoprecipitation where a physical complex is specifically hypothesized.
- **Status:** **Supported hypothesis** for pathway convergence; **insufficient evidence** for lesion-specific physical interactions.

### 5. Therapeutic evaluation of the IL-36/IL-20 inflammatory axis  
**Classification:** Therapeutic target

- **Why prioritize:** The axis is strongly represented and has a biologically testable epithelial inflammatory output.
- **Current evidence:** Large effects for `IL36A`, `IL36G`, `IL19`, and `IL20`, together with antimicrobial and barrier-response genes.
- **External evidence:** Pathway and literature annotations support biological plausibility. The supplied therapeutic records indicate that some selected genes have therapeutic or clinical-trial annotations, but the existence of a drug or trial record does not demonstrate efficacy in psoriasis, and no treatment-response statistic was supplied.
- **Next step:** Compare pathway expression with clinical response in treated patients and test pathway inhibition in keratinocyte–immune co-cultures or lesional explants.
- **Status:** **Exploratory to supported hypothesis**, not an established therapeutic conclusion.

## 5. Major limitations and alternative explanations

1. **Cellular composition and tissue architecture:** Lesional and normal skin likely differ in epidermal thickness and immune-cell abundance. This could inflate both epithelial and myeloid signatures. Single-cell/spatial profiling and histology are the most direct tests.

2. **Disease severity and treatment exposure:** The very large effects may depend on lesion severity, recent topical/systemic therapy, disease duration, or sampling location. Clinical metadata-stratified analysis and paired lesional/nonlesional samples are needed.

3. **Bulk-expression association versus causation:** The data identify genes associated with the lesional state, not initiating drivers. For example, elevated `IL36RN` may be compensatory rather than pathogenic, and increased defensins may be downstream of cytokine activation.

4. **External validation is absent:** The evidence pack explicitly reports independent-cohort validation as unavailable. Pathway recurrence, STRING edges, tissue annotations, and literature records are contextual evidence and may share underlying publications or annotation models.

5. **Annotation and gene-identity uncertainty:** Several loci are `LOC` genes, pseudogene-like or long noncoding transcripts, and their biological functions are less certain. Their statistical effects should be preserved, but mechanistic interpretation should await transcript-identity confirmation and orthogonal measurement.

Overall, the most defensible interpretation is that these lesional samples exhibit a robust, coordinated **inflammatory–antimicrobial–epidermal remodeling state**, with the **IL-36/IL-20 axis and the antimicrobial/cornified-envelope programs** providing the strongest mechanistically testable hypotheses.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=9, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
